본문으로 건너뛰기
CAS 기록 1건

CAS 125-71-3

CAS 125-71-3은(는) 규정 1223/2009의 부속서 II–VI에 걸쳐 EU 부속서 기록 1건과 일치합니다.

CAS 125-71-3의 기록

1 총

화학적 정체 및 특성

CAS 125-71-3의 PubChem 2D 화학 구조
CAS 125-71-3PubChem CID 5360696

Dextromethorphan

Dextromethorphan is a 6-methoxy-11-methyl-1,3,4,9,10,10a-hexahydro-2H-10,4a-(epiminoethano)phenanthrene in which the sterocenters at positions 4a, 10 and 10a have S-configuration. It is a prodrug of dextrorphan and used as an antitussive drug for suppressing cough. It has a role as a oneirogen, a xenobiotic, a prodrug, a neurotoxin, an antitussive, a NMDA receptor antagonist and an environmental contaminant. It is functionally related to a dextrorphan. It is an enantiomer of a levomethorphan. — ChEBI

IUPAC 명칭
(1S,9S,10S)-4-methoxy-17-methyl-17-azatetracyclo[7.5.3.01,10.02,7]heptadeca-2(7),3,5-triene
분자식
C18H25NO
분자량
271.4 g/mol
정확한 질량
271.193614421 Da
XLogP3
3.4
위상 극성 표면적
12.5 Ų
수소 결합 공여체
0
수소 결합 수용체
2
공유결합 단위
1
정의된 입체중심
3

다른 이름

d-Methorphandelta-MethorphanDextromorphanDextromethorfanDextrometorfanoDextromethorphaneAlbutussinDestrometerfano
보고된 명칭 16개 더 보기
DextromethorphanumBA 2666Balminil DM(+)-Dextromethorphan3-Methoxy-17-methyl-9alpha,13alpha,14alpha-morphinanMorphinan, 3-methoxy-17-methyl-, (9alpha,13alpha,14alpha)-DXM [Antitussive]BA-26667355X3ROTSCHEBI:4470(+)-3-Methoxy-N-methylmorphinonNSC-751452DXM (Antitussive)(+)-cis-1,3,4,9,10,10a-Hexahydro-6-methoxy-11-methyl-2H-10,4alpha-iminoethanophenanthren(+)-3-methoxy-17-methyl-9alpha,13alpha,14alpha-morphinanRoboTablets
외부 데이터베이스 식별자

추가 과학 데이터베이스의 근거

NIH PubChem PUG-View
식별자 정확히 일치5360696

Attributed physical-property, hazard, environmental and use annotations.

  • Note: This chemical does not meet GHS hazard criteria for 46.8% (36 of 77) of reports. 출처: European Chemicals Agency (ECHA)
  • Signal: Danger 출처: European Chemicals Agency (ECHA)
  • GHS Hazard Statements: H301 (51.9%): Toxic if swallowed [Danger Acute toxicity, oral] 출처: European Chemicals Agency (ECHA)
  • Precautionary Statement Codes: P264, P270, P301+P316, P321, P330, P405, and P501 (click each P-code to see the statement) 출처: European Chemicals Agency (ECHA)
  • ECHA C&L Notifications Summary: Aggregated GHS information provided per 77 reports by companies from 4 notifications to the ECHA C&L Inventory.; Reported as not meeting GHS hazard criteria per 36 of 77 reports by companies.; There are 3 notifications provided by 41 of 77 reports by companies with hazard statement code(s).; Information may vary between notifications depending on impurities, additives, and other factors. The percentage value in parenthesis indicates the notified classification ratio from companies that provide hazard codes. Only hazard codes with percentage values above 10% are shown. For more detailed information, please visit ECHA C&L website. 출처: European Chemicals Agency (ECHA)
  • Toxicity Summary: IDENTIFICATION AND USE: Dextromethorphan is a white odorless solid crystal or powder. It is an opium alkaloid derivative, which is found in cough and cold preparations. HUMAN STUDIES: Dextromethorphan is a drug of abuse. The main risks associated with dextromethorphan are ataxia, central nervous system (CNS) stimulation, dizziness, lethargy and psychotic behavior. Less frequently with large doses seizures and respiratory depression can occur. Nausea, vomiting, constipation and tachycardia may also occur. CNS effects include ataxia, drowsiness, vertigo and rarely coma. CNS stimulation may be observed. Restlessness, increased muscle tone with body rigidity have been reported. With extremely large ingestions respiratory depression can occur. Gastrointestinal effects include nausea, vomiting, constipation and dry mouth. Urinary retention may be seen. Dextromethorphan abuse has been described and produces euphoria, CNS stimulation, visual and/or auditory hallucinations. Dextromethorphan hydrobromide is the drug form, thus the possibility of bromide poisoning should be considered in the long term abuser. Dextromethorphan enhances serotonin activity by inhibiting the reuptake of serotonin 출처: Hazardous Substances Data Bank (HSDB)
  • Toxicity Summary: Signs and Symptoms of Overdose; One significant concern regarding dextromethorphan toxicity is its OTC misuse, which has steadily increased since the early 2000s. This misuse is referred to by slang terms such as "going pharming," "robotripping," and "dexing." In 2006, three specific OTC product formulations accounted for 66% of reported dextromethorphan misuse cases in the United States, with Coricidin HBP Cough & Cold Tablets and Robitussin products being prominent. A life-threatening toxicity associated with dextromethorphan abuse is serotonin syndrome, resulting from its serotonin reuptake inhibition properties. When combined with SSRIs or MAOIs, the risk of serotonin syndrome increases significantly. Symptoms include agitation, confusion, dilated pupils, headache, tachycardia, hypotension, high fever, seizures, irregular heartbeat, and may progress to unconsciousness.; Despite the rise in misuse, public health efforts and legislative actions restricting the sale of dextromethorphan-containing products to minors have helped stabilize or reduce abuse rates in recent years. However, continued vigilance is essential to prevent misuse and associated toxicities, given dextromethorph 출처: StatPearls
  • Toxicity Summary: Dextromethorphan is an opioid-like drug that binds to and acts as antagonist to the NMDA glutamatergic receptor, it is an agonist to the opioid sigma 1 and sigma 2 receptors, it is also an alpha3/beta4 nicotinic receptor antagonist and targets the serotonin reuptake pump. Dextromethorphan is rapidly absorbed from the gastrointestinal tract, where it enters the bloodstream and crosses the blood-brain barrier. The first-pass through the hepatic portal vein results in some of the drug being metabolized into an active metabolite of dextromethorphan, dextrorphan, the 3-hydroxy derivative of dextromethorphan. 출처: Toxin and Toxin Target Database (T3DB)
  • Environmental Bioconcentration: The estimated pKa of dextromethorphan is 9.8(1), indicating that dextromethorphan will exist almost entirely in the cation form at pH values of 5 to 9 and, therefore, bioconcentration in fish is not expected to be an important fate process(SRC). 출처: Hazardous Substances Data Bank (HSDB)
  • Environmental Fate: TERRESTRIAL FATE: Based on a classification scheme(1), an estimated Koc value of 23,000(SRC), determined from a structure estimation method(2), indicates that dextromethorphan is expected to be immobile in soil(SRC). The estimated pKa of dextromethorphan is 9.8(3), indicating that this compound will exist almost entirely in the cation form in the environment and cations generally adsorb more strongly to soils containing organic carbon and clay than their neutral counterparts(4). Volatilization of the cation from moist soil is not expected because cations do not volatilize(SRC). Dextromethorphan is not expected to volatilize from dry soil surfaces(SRC) based upon an estimated vapor pressure of 1.0X10-5 mm Hg at 25 °C(SRC), determined from a fragment constant method(2). Biodegradation data in soil were not available(SRC, 2017). 출처: Hazardous Substances Data Bank (HSDB)
  • Environmental Fate: AQUATIC FATE: Based on a classification scheme(1), an estimated Koc value of 23,000(SRC), determined from a structure estimation method(2), indicates that dextromethorphan is expected to adsorb to suspended solids and sediment(SRC). An estimated pKa of 9.8(3) indicates dextromethorphan will exist almost entirely in the cation form at pH values of 5 to 9 and, therefore, volatilization from water surfaces and bioconcentration in aquatic organisms are not expected to be an important fate processes(SRC). Dextromethorphan is not expected to undergo hydrolysis in the environment due to the lack of functional groups that hydrolyze under environmental conditions(4). Biodegradation data in water were not available(SRC, 2017). 출처: Hazardous Substances Data Bank (HSDB)
  • Environmental Fate: ATMOSPHERIC FATE: According to a model of gas/particle partitioning of semivolatile organic compounds in the atmosphere(1), dextromethorphan, which has an estimated vapor pressure of 1.0X10-5 mm Hg at 25 °C(SRC), determined from a fragment constant method(2), will exist in both the vapor and particulate phases in the ambient atmosphere. Vapor-phase dextromethorphan is degraded in the atmosphere by reaction with photochemically-produced hydroxyl radicals(SRC); the half-life for this reaction in air is estimated to be 3.3 hours(SRC), calculated from its rate constant of 1.2X10-10 cu cm/molecule-sec at 25 °C(SRC) that was derived using a structure estimation method(2). Particulate-phase dextromethorphan may be removed from the air by wet or dry deposition(SRC). Dextromethorphan contains chromophores that absorb at wavelengths >290 nm(3) and, therefore, is expected to be susceptible to direct photolysis by sunlight(SRC). 출처: Hazardous Substances Data Bank (HSDB)
  • Uses: Antitussive Agents; Excitatory Amino Acid Antagonists 출처: Hazardous Substances Data Bank (HSDB)
  • Uses: Probe to determine cytochrome 450 phenotype 출처: Hazardous Substances Data Bank (HSDB)
  • Uses: MEDICATION 출처: Hazardous Substances Data Bank (HSDB)
  • Uses: Dextromethorphan (DXM) is an over-the-counter (OTC) cough suppressant commonly found in cold medications. DXM is often abused in high doses by adolescents to generate euphoria and visual and auditory hallucinations. Illicit use of DXM is referred to on the street as "Robo-tripping" or "skittling." These terms are derived from the most commonly abused products, Robitussin and Coricidin. 출처: Hazardous Substances Data Bank (HSDB)
  • Uses: Use (kg; approx.) in Germany (2009): >1000; Use (kg) in USA (2002): 38000; Consumption (g per capita; approx.) in Germany (2009): 0.0122; Consumption (g per capita) in the USA (2002): 0.135; Excretion rate: 0.25; Calculated removal (%): 45.3 출처: NORMAN Suspect List Exchange
  • Uses: The primary use of dextromethorphan is as a cough suppressant, for the temporary relief of cough caused by minor throat and bronchial irritation (as commonly accompanies the common cold), as well as those resulting from inhaled irritants. In addition, a combination of dextromethorphan and quinidine has been shown to alleviate symptoms of easy laughing and crying (pseudobulbar affect) in patients with amyotrophic lateral sclerosis and multiple sclerosis. 출처: Toxin and Toxin Target Database (T3DB)

매핑 기준: Existing checksum-valid CAS to unique PubChem CID match. 가져온 시각: 2026-08-31. 출처 기록 열기

과학적 분류와 유해성 주석은 맥락을 제공할 뿐이며, 위에 표시된 시장별 규제 판단을 대체하지 않습니다.

추가 출처 적용 범위 및 일치 상태
출처결과확인됨
NIH PubChem PUG-View정확히 일치2026-08-31

기록된 불일치는 출처를 확인했다는 유용한 근거이며, 해당 물질이 다른 곳에 존재하지 않는다는 주장이 아닙니다.

체크섬이 유효한 CAS 일치를 통해 2026-08-31에 NIH PubChem에서 가져왔습니다. 화학적 특성은 이 페이지의 규제 판단을 대체하지 않습니다.

이 사이트에서 CAS 125-71-3을(를) 사용하는 방식

CAS 125-71-3은(는) 이 페이지를 특정 물질에 고정하는 데 사용하는 Chemical Abstracts Service 식별자입니다. 현재 데이터세트에서는 EU 부속서 기록 1건이 이 식별자를 공유하며, 같은 물질이 하나의 규제 맥락에 나타나는지 여러 맥락에 나타나는지 교차 확인하는 데 도움이 됩니다.

공급업체 규격서, SDS 또는 원료 문서에 CAS 125-71-3이(가) 제시되어 있고 연결된 모든 부속서 II–VI 기록을 한곳에서 확인해야 할 때 이 페이지를 이용하세요. 위의 항목 카드는 농도 한도, 경고 문구, 부속서 위치 및 제품 유형 조건을 가장 빠르게 확인하는 방법입니다.

자주 묻는 질문

CAS 125-71-3로 식별되는 물질은 맥락에 따라 다른 조건이 적용되는 경우 EU 화장품 규정의 여러 부속서에 나타날 수 있습니다. 예를 들어 어떤 물질이 부속서 III에서 특정 조건으로 사용제한될 수 있고, 같은 CAS가 부속서 IV에서 별도의 항목 조건에 따라 허용 색소로 나타날 수도 있습니다. 각 항목은 개별적으로 검토해야 합니다.

CAS 번호를 원료 규격서 및 CoA 문서와 대조하세요. CAS가 부속서 II에 있으면 해당 물질이 없는지 확인하세요. 부속서 III에 있으면 처방에서 농도 한도와 제품 유형 조건이 충족되는지 확인하세요. 이 CAS 번호를 공유하는 모든 부속서 항목이 위에 나열되어 있습니다.

CAS 번호는 미국의 Chemical Abstracts Service가 부여하며 전 세계적으로 통용됩니다. EC 번호는 EINECS, ELINCS 또는 NLP 목록 같은 목록에 수록된 유럽연합 집행위원회 식별자입니다. 두 식별자 모두 EU 화장품 부속서 항목에 나타날 수 있습니다. 두 가지를 모두 가진 물질도 있고, 하나만 가진 물질도 있으며, 일부 오래된 항목은 둘 다 없을 수도 있습니다.

INCI 검사기는 원료명, CAS 번호 및 EC 번호를 받습니다. 이 CAS 번호를 직접 확인한 다음, 결과를 공급업체 규격서 및 연결된 모든 부속서 조건과 대조하세요.

도구 및 다음 단계

처방 확인

전체 INCI 목록을 검사한 다음, CAS 125-71-3을(를) 사용하여 일치한 물질의 공급업체 문서를 교차 확인하세요.

INCI 검사기

부속서 둘러보기

카테고리별로 모든 EU 화장품 규정 부속서를 둘러보세요.

모든 부속서

명칭으로 검색

문서에서 CAS 125-71-3과(와) 함께 나오는 INCI 명칭, 별칭 또는 관련 식별자를 검색하세요.

검색